Market capitalization | €1.64b |
Enterprise Value | €2.23b |
P/E (TTM) P/E ratio | 23.92 |
EV/Sales (TTM) EV/Sales | 3.15 |
P/S ratio (TTM) P/S ratio | 2.32 |
P/B ratio (TTM) P/B ratio | 3.11 |
Revenue growth (TTM) Revenue growth | 7.86% |
Revenue (TTM) Revenue | €707.00m |
EBIT (operating result TTM) EBIT | €90.90m |
As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.
1 Analyst has issued a forecast Biotest:
1 Analyst has issued a forecast Biotest:
Sep '24 |
+/-
%
|
||
Revenue | 707 707 |
8%
8%
|
|
Gross Profit | 240 240 |
6%
6%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 91 91 |
22%
22%
|
Net Profit | 69 69 |
25%
25%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.
Head office | Germany |
CEO | Peter Janssen |
Employees | 2,426 |
Founded | 1946 |
Website | www.biotest.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.